Baird calls rumors of a GlaxoSmithKline (GSK +1.7%) takeout of Biomarin (BMRN +2.2%) "gossip"...


Baird calls rumors of a GlaxoSmithKline (GSK +1.7%) takeout of Biomarin (BMRN +2.2%) "gossip" after an article in the Telegraph suggested the company was in " advanced" talks to acquire the drug developer. Baird notes many details were lacking in the report, and, more curiously, is that such a deal would happen before "transformational data readouts" from clinical studies that are expected by the end of the year. A "takeout does make sense, just not now," the firm asserts.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs